Moderna Stock News

A microbiologist answers 5 questions about how Moderna and Pfizer could rapidly adjust mRNA vaccines

The late-night comedian appears to be skeptical of Moderna CEO Stephane Bancel''s take on the new Omicron variant.

The European Medicines Agency''s safety committee has confirmed a “very rare” risk of myocarditis and pericarditis in individuals who''ve had the Pfizer-BioNTech or Moderna Covid vaccines, having conducted large Europe-wide studies. Read Full Article at RT.com

The post Docusign, Didi Global, Moderna and more appeared on BitcoinEthereumNews.com . Check out the companies making headlines before the bell Friday: DocuSign (DOCU) The software stock sank 32% after its fourth-quarter sales guidance came in at a range of $557

FDA Expedites Review Process For Omicron Vaccines And Drugs It''s been one week since the omicron variant first rattled markets and prompted the Federal Reserve''s latest rethink of its plans for rolling back its monetary stimulus. And in that time, vaccine-makers have talked their book by sharing plans to produce new omicron-targeted vaccines, while others claim that there are no data suggesting the Pfizer-BioNTech jab is less effective against omicron. Assuming the world still does care about omicron three months from now (the first cases of the variant have only just been confirmed in the US in recent days), the FDA and its advisors are reportedly working on an expedited approval process that will allow "tweaked" versions of extant vaccines and remedies to be sheperded through in a matter of weeks. WSJ reports that the FDA has been quietly meeting with drug makers to establish guidelines for expedited approval of the next generation of vaccines, if they''re needed (and that''s still a big "if").

Among the seven Coronavirus vaccines which showed effective immune response are AstraZeneca, Pfizer, Novavax, Janssen, Moderna, Valneva and Curevac.

Robert Langer, co-founder of Moderna, said a new vaccine targeting omicron could be developed quite quickly.

The founder of Moderna has told an Australian investment conference COVID is sticking around for the long haul - and the biotech giant is prepared.

Researchers also say there are signs the boosters would still offer protection against new variant Omicron.

ABC News (Australia) published this video item, entitled … Read more

UK orders 114m extra vaccine doses – enough to keep country supplied with booster shots for two more years. The extra Moderna and Pfizer jabs will be delivered in 2022

BOOSTER jabs should be enough to protect Brits from falling seriously unwell from the Omicron variant, top scientists claim. New data vindicates the UKs decision to offer Pfizer or Moderna as a third shot. In a trial of seven boosters, the two mRNA jabs came out on top triggering the biggest rise in Covid []

Some early studies suggest that Moderna''s vaccine is slightly stronger than Pfizer''s. Moderna''s also comes with slightly heavier side effects.

Only AstraZeneca and Moderna have been approved for use.